What is Aprea Therapeutics, Inc.'s earnings per share (EPS)?

Aprea Therapeutics, Inc. (APRE) reported diluted earnings per share of $-1.93 for fiscal year 2025. This represents a 17.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aprea Therapeutics, Inc. Financials

APRE

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Aprea Therapeutics, Inc. (APRE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

0/9

Aprea Therapeutics, Inc. passes 0 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.02x

For every $1 of reported earnings, Aprea Therapeutics, Inc. generates $1.02 in operating cash flow (-$12.9M OCF vs -$12.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$13.2M

YoY+7.6%

Aprea Therapeutics, Inc.'s EBITDA was -$13.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.6% from the prior year.

Net Income

-$12.6M

YoY+2.8%

Aprea Therapeutics, Inc. reported -$12.6M in net income in fiscal year 2025. This represents an increase of 2.8% from the prior year.

EPS (Diluted)

$-1.93

YoY+17.9%

Aprea Therapeutics, Inc. earned $-1.93 per diluted share (EPS) in fiscal year 2025. This represents an increase of 17.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$14.6M

YoY-36.1%

5Y CAGR-30.3%

Aprea Therapeutics, Inc. held $14.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+49.5%

Aprea Therapeutics, Inc. had 8M shares outstanding in fiscal year 2025. This represents an increase of 49.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-101.3%

YoY-34.1pp

5Y CAGR-32.2pp

Aprea Therapeutics, Inc.'s ROE was -101.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 34.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$7.0M

YoY-24.8%

5Y CAGR-28.6%

Aprea Therapeutics, Inc. invested $7.0M in research and development in fiscal year 2025. This represents a decrease of 24.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

APRE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$7.0M-24.8%	$9.4M+22.8%	$7.6M-53.5%	$16.4M-31.4%	$23.9M-36.9%	$37.9M
SG&A Expenses	$6.5M+0.3%	$6.5M-23.4%	$8.4M-59.8%	$21.0M+54.8%	$13.6M-9.3%	$14.9M
Operating Income	-$13.2M+7.6%	-$14.3M+7.4%	-$15.5M+86.4%	-$113.4M-202.8%	-$37.4M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$12.6M+2.8%	-$13.0M+9.3%	-$14.3M+87.3%	-$112.7M-203.4%	-$37.1M+30.6%	-$53.5M
EPS (Diluted)	$-1.93+17.9%	$-2.35+40.5%	$-3.95+94.2%	$-67.99-94.9%	$-34.88	$-50.61

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$1.6M-14.3%	$1.9M-23.0%	$2.5M	N/A	$2.8M+11.3%	$2.6M+59.8%	$1.6M
SG&A Expenses	N/A	$1.5M-7.1%	$1.6M-9.7%	$1.8M	N/A	$1.6M-13.3%	$1.9M-4.1%	$1.9M
Operating Income	N/A	-$3.1M+8.0%	-$3.4M+17.1%	-$4.1M	N/A	-$4.1M-6.5%	-$3.8M-22.1%	-$3.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	N/A	$0	$0	$0
Net Income	N/A	-$3.0M+8.2%	-$3.2M+17.6%	-$3.9M	N/A	-$3.8M-9.0%	-$3.5M-23.5%	-$2.8M
EPS (Diluted)	N/A	$-0.47+11.3%	$-0.53+19.7%	$-0.66	N/A	$-0.64-10.3%	$-0.58+13.4%	$-0.67

APRE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$15.9M-33.6%	$24.0M+5.9%	$22.7M-24.9%	$30.2M-46.9%	$56.8M-38.8%	$92.8M
Current Assets	$15.6M-34.0%	$23.6M+4.7%	$22.5M-25.3%	$30.2M-46.7%	$56.6M-38.8%	$92.4M
Cash & Equivalents	$14.6M-36.1%	$22.8M+5.8%	$21.6M-24.9%	$28.8M-45.8%	$53.1M-40.4%	$89.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.5M-25.3%	$4.7M-18.0%	$5.7M+78.0%	$3.2M-56.2%	$7.3M-52.5%	$15.4M
Current Liabilities	$2.8M-17.8%	$3.4M-23.4%	$4.4M+37.0%	$3.2M-56.2%	$7.3M-52.3%	$15.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$12.4M-35.6%	$19.3M+13.9%	$17.0M-33.9%	$25.6M-48.2%	$49.5M-36.0%	$77.4M
Retained Earnings	-$333.6M-3.9%	-$321.0M-4.2%	-$308.1M-4.9%	-$293.8M-62.2%	-$181.1M-25.8%	-$144.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$15.9M+11.3%	$14.3M-17.3%	$17.3M-14.4%	$20.2M-15.7%	$24.0M-10.8%	$26.9M-10.2%	$30.0M-9.7%	$33.2M
Current Assets	$15.6M+11.6%	$13.9M-17.6%	$16.9M-14.7%	$19.8M-15.9%	$23.6M-11.0%	$26.5M-10.4%	$29.6M-10.6%	$33.1M
Cash & Equivalents	$14.6M+6.4%	$13.7M-17.0%	$16.5M-14.2%	$19.3M-15.6%	$22.8M-13.0%	$26.2M-8.5%	$28.7M-11.4%	$32.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.5M+2.4%	$3.4M-12.5%	$3.9M-16.6%	$4.7M0.0%	$4.7M-5.6%	$4.9M+12.3%	$4.4M+3.0%	$4.3M
Current Liabilities	$2.8M+3.1%	$2.7M-15.4%	$3.2M-5.8%	$3.4M0.0%	$3.4M-7.6%	$3.6M+17.5%	$3.1M+4.4%	$3.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$12.4M+14.0%	$10.9M-18.6%	$13.4M-13.7%	$15.5M-19.5%	$19.3M-12.0%	$21.9M-14.1%	$25.6M-11.6%	$28.9M
Retained Earnings	-$333.6M-0.7%	-$331.2M-0.9%	-$328.2M-1.0%	-$325.0M-1.2%	-$321.0M-0.9%	-$318.1M-1.2%	-$314.4M-1.1%	-$310.9M

APRE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$12.9M+4.9%	-$13.6M-11.3%	-$12.2M+51.3%	-$25.0M+33.6%	-$37.7M+9.8%	-$41.8M
Capital Expenditures	N/A	$15K-83.4%	$93K	N/A	N/A	$26K
Free Cash Flow	N/A	-$13.6M-10.6%	-$12.3M	N/A	N/A	-$41.8M
Investing Cash Flow	N/A	-$15K+83.4%	-$93K	N/A	N/A	-$26K
Financing Cash Flow	$4.6M-68.7%	$14.8M+188.4%	$5.1M+652.6%	$683K-60.9%	$1.7M+1057.4%	$151K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$3.0M+6.6%	-$3.2M-1.3%	-$3.1M+13.8%	-$3.6M-3.4%	-$3.5M-42.2%	-$2.5M+32.2%	-$3.6M+7.5%	-$3.9M
Capital Expenditures	N/A	N/A	N/A	N/A	$0	$0-100.0%	$8K-6.0%	$8K
Free Cash Flow	N/A	N/A	N/A	N/A	-$3.5M-42.2%	-$2.5M+32.4%	-$3.6M+7.5%	-$3.9M
Investing Cash Flow	N/A	N/A	N/A	N/A	$0	$0+100.0%	-$8K+6.0%	-$8K
Financing Cash Flow	$3.8M+973.2%	$358K-7.0%	$385K+589.1%	$56K-58.4%	$134K+11736.8%	-$1K+94.5%	-$21K-100.1%	$14.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

APRE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-101.3%-34.1pp	-67.1%+17.1pp	-84.3%+355.1pp	-439.3%-364.3pp	-75.0%-5.9pp	-69.1%
Return on Assets	-79.1%-25.0pp	-54.0%+9.0pp	-63.1%+310.5pp	-373.6%-308.3pp	-65.3%-7.7pp	-57.6%
Current Ratio	5.63-1.4	7.01+1.9	5.14-4.3	9.42+1.7	7.73+1.7	6.03
Debt-to-Equity	0.28+0.0	0.24-0.1	0.34+0.2	0.12-0.0	0.15-0.1	0.20
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-27.2%-3.1pp	-24.1%+1.2pp	-25.3%	N/A	-17.2%-3.7pp	-13.6%-3.9pp	-9.7%
Return on Assets	N/A	-20.8%-2.1pp	-18.7%+0.7pp	-19.4%	N/A	-14.1%-2.5pp	-11.6%-3.1pp	-8.5%
Current Ratio	5.63+0.4	5.20-0.1	5.34-0.6	5.90-1.1	7.01-0.3	7.28-2.3	9.55-1.6	11.15
Debt-to-Equity	0.28-0.0	0.31+0.0	0.29-0.0	0.30+0.1	0.24+0.0	0.23+0.1	0.17+0.0	0.15
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Cyclacel Phar Pr CYCCP

$9.6M

In8Bio, Inc. INAB

$14.6M

Transcode Therapeutics Inc RNAZ

$7.9M

KIORA PHARMACEUTICALS INC KPRX

$7.6M

Aeon Biopharma AEON

$24.9M

Frequently Asked Questions

Is Aprea Therapeutics, Inc. profitable?

No, Aprea Therapeutics, Inc. (APRE) reported a net income of -$12.6M in fiscal year 2025.

What is Aprea Therapeutics, Inc.'s EBITDA?

Aprea Therapeutics, Inc. (APRE) had EBITDA of -$13.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Aprea Therapeutics, Inc.'s return on equity (ROE)?

Aprea Therapeutics, Inc. (APRE) has a return on equity of -101.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Aprea Therapeutics, Inc.'s operating cash flow?

Aprea Therapeutics, Inc. (APRE) generated -$12.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aprea Therapeutics, Inc.'s total assets?

Aprea Therapeutics, Inc. (APRE) had $15.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Aprea Therapeutics, Inc. spend on research and development?

Aprea Therapeutics, Inc. (APRE) invested $7.0M in research and development during fiscal year 2025.

How many shares does Aprea Therapeutics, Inc. have outstanding?

Aprea Therapeutics, Inc. (APRE) had 8M shares outstanding as of fiscal year 2025.

What is Aprea Therapeutics, Inc.'s current ratio?

Aprea Therapeutics, Inc. (APRE) had a current ratio of 5.63 as of fiscal year 2025, which is generally considered healthy.

What is Aprea Therapeutics, Inc.'s debt-to-equity ratio?

Aprea Therapeutics, Inc. (APRE) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aprea Therapeutics, Inc.'s return on assets (ROA)?

Aprea Therapeutics, Inc. (APRE) had a return on assets of -79.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aprea Therapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Aprea Therapeutics, Inc. (APRE) had $14.6M in cash against an annual operating cash burn of $12.9M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Aprea Therapeutics, Inc.'s Piotroski F-Score?

Aprea Therapeutics, Inc. (APRE) has a Piotroski F-Score of 0 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aprea Therapeutics, Inc.'s earnings high quality?

Aprea Therapeutics, Inc. (APRE) has an earnings quality ratio of 1.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.